Filing Details
- Accession Number:
- 0000919574-23-004543
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-11 17:01:57
- Reporting Period:
- 2023-08-09
- Accepted Time:
- 2023-08-11 17:01:57
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
834365 | Biolife Solutions Inc | BLFS | Electromedical & Electrotherapeutic Apparatus (3845) | 943076866 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1534260 | Casdin Partners Gp, Llc | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | No | No | Yes | No | |
1534261 | Casdin Capital, Llc | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | No | No | Yes | No | |
1534264 | Eli Casdin | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | No | No | Yes | No | |
1534265 | Casdin Partners Master Fund, L.p. | 1350 Avenue Of The Americas Suite 2600 New York NY 10019 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $.001 Per Share | Acquisiton | 2023-08-09 | 58,465 | $13.20 | 7,630,000 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock, Par Value $.001 Per Share | 150,000 | Indirect | See footnote |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $13.1151 to $13.3998. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin Capital"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ("Casdin GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.
- The securities are owned directly by a client of Casdin Capital and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, the investment adviser to such client; (ii) Casdin GP, the general partner of such client, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.